Advaxis Inks Deal with Sellas to Develop New Cancer Immunotherapy – Xconomy
Xconomy |
Advaxis Inks Deal with Sellas to Develop New Cancer Immunotherapy
Xconomy Advaxis and Sellas Life Sciences Group, two companies that have pursued different ways of prompting the body's immune system to fight cancer, are now hoping that combining their efforts will lead to a more precise treatment. The agreement between the … Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy |
